NCT03409198: Phase IIb Study Evaluating Immunogenic Chemotherapy Combined With Ipilimumab and Nivolumab in Breast Cancer

NCT03409198
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Must have luminal B breast cancer that is ER+
Exclusions: BRCA 1/2+; Untreated symptomatic CNS metastases- see trial for details
https://ClinicalTrials.gov/show/NCT03409198

Comments are closed.

Up ↑